**Table F-3. Subgroup analysis of included randomized trials: reduction, remission, and loss of diagnosis**

| AuthorYear | Intervention Groups | Subgroup Analyzed | PTSD SymptomReduction | Remission  | Loss of Diagnosis |
| --- | --- | --- | --- | --- | --- |
| Connor et al., 1999[170](#_ENREF_170)Meltzer-Brody et al., 2000[171](#_ENREF_171) | G1: Fluoxetine10 to 60mg/dayG2: Placebo | Individuals with specific PTSD symptoms | Meltzer-Brody et al., 2000[171](#_ENREF_171)Symptom-Specific Effects-DTSMean (SD)Within-Group Mean Change (Endpoint-Baseline)IntrusionBaselineG1 Baseline: 17.7G1 Post-tx: 6.7Change: -11.0G2 Baseline: 21.5G2 Post-tx: 13.5Change: -8.0p=0.0082AvoidanceBaseline: G1 Baseline: 9.2G1 Post-tx: G1: 3.0Change: -6.2G2 Baseline: 9.3G2 Post-tx: 6.3Change:-3.0p=0.0153NumbingBaseline: G1 Baseline: 22.3G1 Post-tx: 6.2Change: -16.1G2 Baseline: 22.6G2 Post-tx: 15.1Change: -7.5p=0.0017 |  NR | NR |

| AuthorYear | Intervention Groups | Subgroup Analyzed | PTSD SymptomReduction | Remission  | Loss of Diagnosis |
| --- | --- | --- | --- | --- | --- |
| Connor et al., 1999[170](#_ENREF_170)Meltzer-Brody et al., 2000[171](#_ENREF_171)(continued) |   |   | HyperarousalBaseline: G1Baseline: 24.7G1 Post-tx: 9.0Change: -15.7G2 Baseline: 26.0G2 Post-tx: 17.3Change: -8.7p=0.0029SIPIntrusionBaselineG1 Baseline: 10.1 G1 Post-tx: 2.9Change: 7.2G2 Baseline: 9.6 G2 Post-tx: 5.5Change: 4.1p=0.0108AvoidanceBaseline: G1 Baseline: 3.9 G1 Post-tx: 1.1Change: 2.8G2 Baseline: 4.1 G2 Post-tx: 2.5Change: 1.6p=0.0189 |   |   |

| AuthorYear | Intervention Groups | Subgroup Analyzed | PTSD SymptomReduction | Remission  | Loss of Diagnosis |
| --- | --- | --- | --- | --- | --- |
| Connor et al., 1999[170](#_ENREF_170)Meltzer-Brody et al., 2000[171](#_ENREF_171)(continued) |   |   | NumbingG1 Baseline: 9.6G2 Baseline: 10.2Change: 7.1G1Post-tx: 2.5G2 Post-tx: 5.8Change: 4.4p=0.0028HyperarousalG1 Baseline: 10.5G1 Post-tx: 3.6Change: 6.9G2 Baseline: 10.8G2 Post-tx: 6.6Change: 4.2p=0.0118 |   |   |
| Davidson et al., 2001[68](#_ENREF_68) | G1: Sertraline50 to 200 mg/dayG2: Placebo | Gender | CAPS-2Treatment X Sex analysis was performed but was found to be not significant. | NR | NR |
| Davidson et al., 2007[166](#_ENREF_166) | G1: Tiagabine4 to16mg/dayG2: Placebo | GenderLength of PTSD Diagnosis | CAPSFor those with PTSD, 3 yrs:Mean Change from Baseline:G1: 39.3 (25.9), p=NRG2: 31.2 (27.9), p=NRFor Women:Mean Change from Baseline: G1: 35.0 (24.8), p=NRG2: 22.4 (33.4), p=NR | NR | NR |

| AuthorYear | Intervention Groups | Subgroup Analyzed | PTSD SymptomReduction | Remission  | Loss of Diagnosis |
| --- | --- | --- | --- | --- | --- |
| Foa et al., 1999[14](#_ENREF_14)Zoellner et al., 1999[134](#_ENREF_134) | G1: CBT, exposure-based therapy (PE)G2: CBT, coping skills therapy SITG3: CBT-mixed Combined treatment (PE and SIT Training)G4: WL | Racial/ethnic minority | PSS-I, Mean (SD)African AmericanG1 Pre-tx: 28.48 (7.82)G1 Post- tx: 14.35 (8.78)G1 12 mth FU: 13.43 (11.00)G2 Pre-tx: 35.00 (8.69)G2 Post-tx: 29.20 (8.61)G2 12 mth FU: NRCaucasianG1 Pre-tx: 30.27 (8.90)G1 Post-tx: 11.76 (8.23)G1 12 mth FU: 18.99 (12.30)G2 Pre-tx: 31.90 (4.09)G2 Post-tx: 25.80 (8.63)G2 12 mth FU: NRMain effects of treatment, p<0.001 | NR | NR |

| AuthorYear | Intervention Groups | Subgroup Analyzed | PTSD SymptomReduction | Remission  | Loss of Diagnosis |
| --- | --- | --- | --- | --- | --- |
| Friedman et al., 2007[70](#_ENREF_70) | G1: Sertraline25 to 200 mg/dayG2: Placebo | GenderSubstance Abuse HistorySeverity Level | CAPS-2Trauma typeAdjusted mean Change at Endpoint (SE)Noncombat: -22.2 (4.4)Combat: -11.7 (2.4) Main Effects, p=0.039IESTrauma TypeAdjusted mean Change at Endpoint (SE)Group 1Noncombat: -7.1 (3.7)Combat: -9.2 (2.0)Group 2Noncombat: -18.7 (3.7)Combat: -4.4 (2.1)GenderAdjusted mean Change at Endpoint (SE)MaleG1:-9.6 (2.0)G2: -6.5 (2.0)FemaleG1: -4.2 (4.3)G2: -16.5 (4.6)TX X Gender interaction, p<0.027Pairwise comparisons, NSIllness severityAdjusted mean Change at Endpoint (SE): Data NRGreater change in more severely ill Main Effects, p=0.17 | NR | NR |

| AuthorYear | Intervention Groups | Subgroup Analyzed | PTSD SymptomReduction | Remission  | Loss of Diagnosis |
| --- | --- | --- | --- | --- | --- |
| Markowitz et al., 2015[132](#_ENREF_132)Markowitz et al., 2016[261](#_ENREF_261) | G1: PE G2: IPTG3: RT | Major Depression vs. No Major DepressionTrauma Type: Sexual, Physical, InterpersonalGenderPrimary Trauma Age | CAPSMajor Depressive Subgroup vs.No Major Depressive Disorder Subgroup Difference between Pre-tx to post-tx did not differ significantly between groups p=nsSexual Trauma vs. No Sexual TraumaG1 vs. G2, p = .0244G1 vs. G3, p = 0.282G2 vs. G3, p = 0.7742Physical Trauma vs. No Physical TraumaG1 vs. G2, p = 0.7244G1 vs. G3, p = 0.5670G2 vs. G3, p = 0.5954Interpersonal Trauma vs. No Interpersonal TraumaG1 vs. G2, p = 0.1326G1 vs. G3, p = 0.3797G2 vs. G3, p = 0.3886Female vs. MaleG1 vs. G2, p = 0.0355G1 vs. G3, p = 0.2394G2 vs. G3, p = 0.6761Primary Trauma age<18 vs. Primary Trauma >18G1 vs. G2, p = 0.0633G1 vs. G3, p = 0.1585G2 vs. G3, p = 0.6217 | Remission (CAPS score <20), Major Depressive Disorder SubgroupG1: 26%G2: 23%G3: 22 %Remission (CAPS score <20), No Major Depressive Disorder SubgroupPre-tx to post-tx within group differenceG1: p=0.008G2: 0=0.032G3: NRG1 vs. G3 Difference: p<0.05 (higher remission)G2 vs. G3 Difference: p<0.05 (higher remission) | NR |

| AuthorYear | Intervention Groups | Subgroup Analyzed | PTSD SymptomReduction | Remission  | Loss of Diagnosis |
| --- | --- | --- | --- | --- | --- |
| Marshall et al., 2001[64](#_ENREF_64) | G1: Paroxetine20 mg/day G2: Paroxetine40 mg/dayG3: Placebo | GenderDepressed vs. Nondepressed | CAPS-2Adjusted Mean Differences (95% CI)MenG1 vs. G3: -11.7 (-23.3 to -0.1), p<0.05G2 vs. G3:-13.4 (-24.6 to -2.2), p=0.02WomenG1 vs. G3:-13.7 (-20.4 to -6.9), p<0.001G2 vs. G3:-11.2 (-18.0 to -4.3), p=0.002NondepressedG1 vs. G3:-16.8 (-23.7 to -9.8), p<0.001G2 vs. G3:-12.7 (-19.8 to -5.6), p<0.001DepressedG1 vs. G3: -11.0 (-20.4 to -1.7), p<0.03G2 vs. G3: -11.8 (-20.9 to -2.7), p<0.02 | NR | NR |

| AuthorYear | Intervention Groups | Subgroup Analyzed | PTSD SymptomReduction | Remission  | Loss of Diagnosis |
| --- | --- | --- | --- | --- | --- |
| Martenyi et al., 2002[61](#_ENREF_61)Martenyi et al., 2006[173](#_ENREF_173) | G1: Fluoxetine20 to 80 mg/dayG2: Placebo | GenderRacial/ethnic minorityTrauma TypeNumber of TraumasDifferent SymptomsMilitary Veterans | Martenyi et al., 2002[61](#_ENREF_61)TOP-8Changes from Pre-tx to Post-txLeast Square Mean, (SE), p - valueMaleG1: -9.8 (0.49)G2: -7.8 (0.77), p=0.026FemaleG1: -10.8 (1.25)G2: -6.9 (2.54), p=0.169WhiteG1: -9.8 (0.47)G2: -7.4 (0.76)NonwhiteG1: -14.4 (1.09)G2: -18.2 (2.53), p=0.156Combat Related YesG1: -9.4 (0.72)G2: -5.0 (1.10), p<0.001Combat Related NoG1: -10.3 (0.65)G2: -9.6 (1.05), p=0.543Number of Traumas, One Trauma OnlyG1: -9.9 (0.61)G2: -9.7 (1.00), p=0.847Number of Traumas, ≥ 2 traumasG1: -9.9 (0.74)G2: -5.1 (1.16), p<.001 | NR | NR |

| AuthorYear | Intervention Groups | Subgroup Analyzed | PTSD SymptomReduction | Remission  | Loss of Diagnosis |
| --- | --- | --- | --- | --- | --- |
| Martenyi et al., 2002[61](#_ENREF_61)Martenyi et al., 2006[173](#_ENREF_173)(continued) |   |   | Dissociative SymptomsDES total score = 0G1: -9.9 (0.69)G2: -4.4 (1.17), p<0.001Dissociative SymptomsDES total score > 0G1: -10.7 (0.55)G2: -9.8 (0.89), p=0.383Martenyi et al., 2006[173](#_ENREF_173)TOP-8Mean Difference, 95% CI-3.86 (-6.12 to -1.60), p=0.001CAPSMean Difference, 95% CI-15.05 (-23.80 to -6.30), p<0.001DTSMean Difference, 95% CI-12.88 (-23.97 to -1.79), p=0.023 |   |   |
| Monson et al., 2006[1](#_ENREF_1) | G1:CBT, CPTG2: WL | Comorbid conditions | NR | NR | Loss of PTSD Diagnosis:Endpoint:Disabled: 33%Non-disabled: 47%1 month f/u:Disabled: 33%Non-disabled: 27% |

| AuthorYear | Intervention Groups | Subgroup Analyzed | PTSD SymptomReduction | Remission  | Loss of Diagnosis |
| --- | --- | --- | --- | --- | --- |
| Mueser et al., 2008[7](#_ENREF_7) | G1: CBT-mixed (CBT for PTSD) G2: UC | Severity Level | CAPSMean (SD)Severe, CAPS > 65 G1 Pre-tx: 82.05 (14.46)G1 Post-tx: 59.68 (29.12)G1 3 mth FU: 57.23 (26.92)G1 6mth FU: 62.78 (25.01)G2 Pre-tx: 83.87 (12.45)G2 Post-tx: 79.65 (18.41)G2 3 mth FU: 74.50 (22.17)G2 6 mth FU: 74.24 (23.54)Group effect, p=0.004Mild/Moderate, CAPS <65 G1 Pre-tx: 54.73 (4.74)G1 Post-tx: 40.71 (17.56)G1 3mth FU: 49.25 (23.77)G1 6 mth FU: 45.30 (22.73)G2 Pre-tx:56.07 (9.16)G2 Post-tx: 33.86 (15.40)G2 3 mth FU: 36.78 (25.83)G2 6 mth FU: 52.00 (21.93)Group Effect, p =.77 | NR | NR |

| AuthorYear | Intervention Groups | Subgroup Analyzed | PTSD SymptomReduction | Remission  | Loss of Diagnosis |
| --- | --- | --- | --- | --- | --- |
| Resick et al., 2002[3](#_ENREF_3)Resick et al., 2003[125](#_ENREF_125)Resick et al., 2012[126](#_ENREF_126) | G1: CBT, CPTG2: CBT, exposure-based therapy (PE)G3: WL | Exposed to Child Trauma | CAPSMean (SD)No Childhood Sexual AbusePre-tx: 70.6 (18.9)Post-tx: 28.0 (20.7)9 mth FU: 10.9 (9.1)Childhood Sexual AbusePre-tx: 76.8 (18.4)Post-tx: 28.4 (27.1)9 mth FU: 33.3 (29.6)Time effect, p=0.000Group effect, NSGroup X Time, NS | NR | NR |
| Tucker et al., 2001[65](#_ENREF_65) | G1: Paroxetine20 to 50mg/dayG2: Placebo | Gender | CAPS-2Adjusted Mean Differences (95% CI),G1 vs. G2Men:-15.15 (-24.31 to -5.98)Women: -10.00 (-18.68 to -3.30) | NR | NR |

| AuthorYear | Intervention Groups | Subgroup Analyzed | PTSD SymptomReduction | Remission  | Loss of Diagnosis |
| --- | --- | --- | --- | --- | --- |
| van der Kolk et al., 2007[47](#_ENREF_47) | G1: EMDRG2: Fluoxetine10 to 60 mg/dayG3: Placebo | Exposure to Child Trauma | CAPSMean (SD) Child-onsetG1 Post-tx: 38.36 (20.73)G1 6 mth FU: 33.00 (22.34)G2 Post-tx: 40.20 (14.33)G2 6 mth FU: 50.43 (8.24)G3 Post-tx: 46.57 (20.18)G3 6 mth FU: NRAdult-onset:G1 Post-tx: 19.92 (14.64)G1 6 mth FU: 20.17 (19.36)G2 Post-tx: 37.75 (23.69)G2 6 mth FU:35.36 (16.76)G3 Post-tx: 31.92(13.87)G3 6 mth FU: NROnset X Treatment Effect, NSPatients with adult-onset had greater reductions in PTSD symptoms than those with child-onset at post-tx & 6 mth; p<0.005 (ITT), p=0.02 (Completer) | Asymptomatic at Posttreatment, %Child-onsetG1: 9.1G2: 10.0G3: 7.1Adult-onsetG1: 46.2G2: 18.8G3: 16.7Asymptomatic at Followup, %Child-onsetG1: 33.3G2: 0.0G3: NRAdult-onsetG1: 75.0G2: 0.0G3: NRAdult-onset more likely to achieve asymptomatic end-state function in G1 only (Chi-square, ITT) Posttreatment, p=0.037Followup, p=0.045 | Lost of PTSD Diagnosis at Posttreatment, %Child-onsetG1: 72.7G2: 90.0G3: 57.1Adult-onsetG1: 100.0G2: 75.0G3: 75.0Lost of PTSD Diagnosis at Followup, %Child-onsetG1: 88.9 G2: 42.9G3: NRAdult-onsetG1: 91.7G2: 90.9G3: NRAdult-onset more likely to lose diagnosis in G1 only (Chi-square, ITT)Posttreament, p=0.052Followup, p=0.045G2, adult-onset more likely to lose diagnosis than child-onset, p=0.036 |

CAPS = Clinician-administered PTSD Scale; CI = confidence interval; DTS = Davidson Trauma Scale; IES = Impact of Events Scale; NA = not applicable; NR= not reported; PSS-I= PTSD Symptom Scale Interview; PTSD= Post-Traumatic Stress Disorder; SD = standard deviation; SE = standard error; TOP-8 = Treatment Outcome PTSD Scale